Colloidal silver proteins were marketed as “patent medicines” in the 1880s for treatment of tetanus, rheumatism, and other disorders. In the first part of the 20th century, they were used to treat the common cold and gonorrhea. Marketing of colloidal silver emerged again around 1990 (Fung et al., 1995). In the fall of 2001, reports of bioterrorism attacks using anthrax sent through the U.S. mail prompted the mayor of Howie-in-the-Hills, Florida to officially endorse the use of colloidal silver by townspeople to prevent anthrax (Siegel, 2001).
Unable to display preview. Download preview PDF.
- Bretano L, Margraf H, Monafo WW, Moyer CA. Antibacterial efficacy of a colloidal silver complex. Surg Forum 1966; 17: 76–8.Google Scholar
- FDA. FDA issues final rule on OTC drug products containing colloidal silver. FDA Talk Paper, Food and Drug Administration, U.S. Department of Health and Human Services, August 17, 1999. Avaialble from: URL: http://www.fda/gov/bbs/topics/ANSWERS/ANS00971.html. Accessed November 13, 2001.
- Julshamn K, Andersen KJ, Vik H. Determination of silver biological samples using Zeeman graphite furnace atomic absorption spectrometry. Acta Pharmacol Toxicol Suppl 1986; 7: 613–15.Google Scholar
- Siegel R. Colloidal silver. All Things Considered, National Public Radio (NPR) broadcast, October 23, 2001.Google Scholar